KeyCorp Issues Positive Forecast for ResMed (NYSE:RMD) Stock Price

ResMed (NYSE:RMD) had its price target boosted by KeyCorp from $267.00 to $277.00 in a research note released on Friday morning,Benzinga reports. KeyCorp currently has an overweight rating on the medical equipment provider’s stock.

A number of other equities research analysts have also recently commented on RMD. Piper Sandler decreased their price objective on ResMed from $233.00 to $225.00 and set a “neutral” rating for the company in a research note on Friday, August 7th. Wells Fargo & Company dropped their price objective on shares of ResMed from $225.00 to $215.00 and set an “equal weight” rating on the stock in a report on Friday, August 7th. Mizuho set a $270.00 price objective on shares of ResMed in a report on Friday. Rothschild & Co Redburn assumed coverage on ResMed in a research report on Wednesday, August 19th. They set a “neutral” rating and a $230.00 price target for the company. Finally, Jefferies Financial Group lowered their price objective on shares of ResMed from $240.00 to $225.00 and set a “hold” rating on the stock in a research note on Friday, July 10th. Seven equities research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $253.69.

ResMed Price Performance

NYSE:RMD opened at $230.76 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.42 and a current ratio of 3.10. The company has a 50-day moving average of $231.87 and a 200-day moving average of $225.43. The company has a market capitalization of $32.45 billion, a price-to-earnings ratio of 21.02, a PEG ratio of 1.55 and a beta of 0.75. ResMed has a 52 week low of $180.26 and a 52 week high of $277.67.

ResMed (NYSE:RMD) last announced its quarterly earnings results on Thursday, October 29th. The medical equipment provider reported $2.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.67 by $0.24. The firm had revenue of $1.41 billion during the quarter, compared to the consensus estimate of $1.39 billion. ResMed had a net margin of 27.79% and a return on equity of 25.90%. The firm’s quarterly revenue was up 5.9% on a year-over-year basis. During the same period last year, the firm posted $2.55 EPS. As a group, equities research analysts anticipate that ResMed will post 12.11 earnings per share for the current fiscal year.

ResMed Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 17th. Stockholders of record on Thursday, November 12th will be paid a dividend of $0.66 per share. The ex-dividend date is Thursday, November 12th. This represents a $2.64 dividend on an annualized basis and a dividend yield of 1.1%. ResMed’s dividend payout ratio (DPR) is 25.31%.

Insider Activity

In related news, Director Peter Farrell sold 970 shares of the company’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $234.73, for a total value of $227,688.10. Following the transaction, the director directly owned 51,803 shares in the company, valued at approximately $12,159,718.19. This represents a 1.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, General Counsel Michael Rider sold 400 shares of the stock in a transaction that occurred on Friday, October 23rd. The stock was sold at an average price of $255.00, for a total transaction of $102,000.00. Following the transaction, the general counsel owned 12,318 shares in the company, valued at approximately $3,141,090. The trade was a 3.15% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 24,343 shares of company stock valued at $5,396,098. 0.58% of the stock is owned by company insiders.

Institutional Investors Weigh In On ResMed

Institutional investors and hedge funds have recently bought and sold shares of the company. Bell Investment Advisors Inc acquired a new position in shares of ResMed in the 2nd quarter valued at approximately $26,000. Trust Co. of Vermont bought a new position in ResMed in the second quarter valued at approximately $39,000. Kelleher Financial Advisors acquired a new stake in shares of ResMed in the 2nd quarter valued at $47,000. Provenance Wealth Advisors LLC acquired a new position in shares of ResMed during the 3rd quarter worth $55,000. Finally, Ballast Advisors LLC bought a new stake in shares of ResMed during the 1st quarter worth $84,000. Institutional investors own 54.98% of the company’s stock.

Key Stories Impacting ResMed

Here are the key news stories impacting ResMed this week:

• Positive Sentiment: Quarterly results exceeded expectations. ResMed reported fiscal Q1 2027 adjusted earnings of $2.91 per share versus the $2.67 consensus estimate, while revenue rose 5.9% year over year to $1.41 billion, ahead of the $1.39 billion forecast. ResMed fiscal first-quarter results
• Positive Sentiment: Profitability and demand trends improved. Sustained demand for sleep devices, productivity gains and gross-margin expansion supported the earnings beat. EPS increased from $2.55 in the year-ago quarter, and ResMed reported a 26.94% net margin. ResMed earnings and margin growth
• Positive Sentiment: Analysts raised price targets. RBC increased its target from $262 to $288 and assigned an “outperform” rating. KeyCorp raised its target from $267 to $277 with an “overweight” rating, while Wells Fargo lifted its target from $215 to $250 and maintained “equal weight.” Citigroup raised its target from $240 to $270 but retained a “neutral” rating. Analyst target changes
• Neutral Sentiment: ResMed declared a quarterly dividend of $0.66 per share, or $2.64 annualized, representing an approximately 1.1% yield. The dividend supports shareholder returns but is unlikely to be the primary near-term stock catalyst.
• Negative Sentiment: Full-year guidance was unchanged. The lack of an outlook increase may have disappointed investors who expected the earnings beat and improving margins to result in raised expectations. The neutral ratings from Citigroup and Wells Fargo may also limit the impact of the higher price targets. ResMed maintains prior guidance

About ResMed

ResMed Inc is a medical equipment and software company that develops solutions for sleep-disordered breathing, respiratory conditions and other chronic diseases. The company is best known for its positive airway pressure (PAP) devices used to treat obstructive sleep apnea, along with masks, accessories and related patient support services.

ResMed also provides cloud-connected health technology, including remote-monitoring platforms and software used by healthcare providers, medical equipment suppliers and care organizations.